Prestige Consumer Healthcare (NYSE:PBH) Issues Earnings Results

Prestige Consumer Healthcare (NYSE:PBH) announced its quarterly earnings data on Thursday. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Trading Up 14.6 %

PBH stock traded up $11.11 during midday trading on Thursday, hitting $87.21. The stock had a trading volume of 768,028 shares, compared to its average volume of 306,855. The business has a fifty day moving average price of $79.13 and a two-hundred day moving average price of $75.26. Prestige Consumer Healthcare has a 1-year low of $60.00 and a 1-year high of $87.39. The firm has a market cap of $4.31 billion, a P/E ratio of 21.22, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Wall Street Analyst Weigh In

PBH has been the subject of a number of research analyst reports. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. DA Davidson restated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.25.

Insider Activity

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,810 shares of company stock worth $3,187,300. Company insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.